公开(公告)号：WO03037164A3

公开(公告)日：2003-12-18

申请号：PCT/US0234565

申请日：2002-10-28

Applicant: MILLENNIUM PHARM INC ,  CARROLL JOSEPH M

Inventor： CARROLL JOSEPH M

IPC: A61K31/00 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P7/04 ,  A61P7/06 ,  A61P31/18 ,  A61P31/22 ,  A61P33/02 ,  A61P33/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/00 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/37 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/567 ,  A01N43/04 ,  A61K49/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/63 ,  C12P19/34

CPC classification number: G01N33/6893 ,  G01N2800/00 ,  G01N2800/22

Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood disorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression. In another aspect, the invention provides methods for increasing a hematopoietic cell proliferation in a subject and methods for modulating hematopoietic cell apoptosis in a subject.

Abstract translation: 本发明涉及用于诊断和治疗血液病的方法和组合物，所述血液学病症包括但不限于先天性贫血，血友病，镰状细胞性贫血，地中海贫血，失血和其他血液病症，例如与骨髓有关的血液病症 照射或化疗治疗或肾功能衰竭。 本发明还提供了鉴定能够治疗血液病的化合物的方法。 本发明还提供了用于鉴定能够调节造血细胞活性的化合物的方法。 另外，本发明提供了调节造血细胞活性的方法。 另外，本发明提供了治疗患有以异常2777多肽活性或异常2777核酸表达为特征的血液病症的受试者的方法。 另一方面，本发明提供了增加受试者中造血细胞增殖的方法和调节受试者中造血细胞凋亡的方法。

公开(公告)号：WO2003037164A2

公开(公告)日：2003-05-08

申请号：PCT/US2002/034565

申请日：2002-10-28

Applicant: MILLENNIUM PHARMACEUTICALS, INC. ,  CARROLL, Joseph, M.

Inventor： CARROLL, Joseph, M.

IPC: A61B

CPC classification number: G01N33/6893 ,  G01N2800/00 ,  G01N2800/22 ,  Y02A50/58

Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g. , blood disorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression. In another aspect, the invention provides methods for increasing a hematopoietic cell proliferation in a subject and methods for modulating hematopoietic cell apoptosis in a subject.

Abstract translation: 本发明涉及用于诊断和治疗血液学疾病的方法和组合物，包括但不限于恶性贫血，血友病，镰状细胞性贫血，血管紧张素血症，失血和其他血液病症，例如与骨髓相关的血液病 照射或化学疗法治疗或肾衰竭。 本发明还提供了鉴定能够治疗血液病症的化合物的方法。 本发明还提供了鉴定能调节造血细胞活性的化合物的方法。 此外，本发明提供了调节造血细胞活性的方法。 此外，本发明提供了一种用于治疗以异常2777多肽活性或异常2777核酸表达为特征的血液病症的受试者的方法。 另一方面，本发明提供了增加受试者的造血细胞增殖的方法和调节受试者造血细胞凋亡的方法。

公开(公告)号：WO2003038110A3

公开(公告)日：2003-05-08

申请号：PCT/US2002/034194

申请日：2002-10-25

Applicant: MILLENNIUM PHARMACEUTICALS, INC. ,  CARROLL, Joseph, M.

Inventor： CARROLL, Joseph, M.

IPC: C12Q1/48

Abstract: The invention provides isolated nucleic acids molecules, designated 7118 nucleic acid molecules, which encode novel arginine N-methyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 7118 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 7118 gene has been introduced or disrupted. The invention still further provides isolated 7118 proteins, fusion proteins, antigenic peptides and anti-7118 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

公开(公告)号：WO2002066609A3

公开(公告)日：2002-08-29

申请号：PCT/US2002/004473

申请日：2002-02-15

Applicant: MILLENNIUM PHARMACEUTICALS, INC. ,  KAPELLER-LIBERMANN, Rosana ,  CARROLL, Joseph, M.

Inventor： KAPELLER-LIBERMANN, Rosana ,  CARROLL, Joseph, M.

IPC: C12N9/64

Abstract: The invention provides isolated nucleic acids molecules, designated 23565 nucleic acid molecules, which encode novel zinc carboxypeptidase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23565 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 23565 gene has been introduced or disrupted. The invention still further provides isolated 23565 proteins, fusion proteins, antigenic peptides and anti-23565 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

公开(公告)号：WO2002066609A2

公开(公告)日：2002-08-29

申请号：PCT/US2002/004473

申请日：2002-02-15

Applicant: MILLENNIUM PHARMACEUTICALS, INC. ,  KAPELLER-LIBERMANN, Rosana ,  CARROLL, Joseph, M.

Inventor： KAPELLER-LIBERMANN, Rosana ,  CARROLL, Joseph, M.

IPC: C12N

CPC classification number: C12N9/48 ,  A01K2217/05 ,  A61K38/00 ,  C07K2319/00

Abstract: The invention provides isolated nucleic acids molecules, designated 23565 nucleic acid molecules, which encode novel zinc carboxypeptidase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23565 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 23565 gene has been introduced or disrupted. The invention still further provides isolated 23565 proteins, fusion proteins, antigenic peptides and anti-23565 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供编码新的锌羧肽酶成员的分离的核酸分子，命名为23565核酸分子。 本发明还提供了反义核酸分子，含有23565个核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已引入或破坏23565基因的非人转基因动物。 本发明还进一步提供了分离的23565蛋白，融合蛋白，抗原肽和抗-23565抗体。 还提供了利用本发明组合物的诊断方法。

公开(公告)号：WO2003065871A2

公开(公告)日：2003-08-14

申请号：PCT/US2003/002484

申请日：2003-01-28

Applicant: MILLENNIUM PHARMACEUTICALS INC. ,  CARROLL, Joseph, M. ,  HEALY, Aileen ,  WEICH, Nadine, S. ,  KELLY, Louise, M.

Inventor： CARROLL, Joseph, M. ,  HEALY, Aileen ,  WEICH, Nadine, S. ,  KELLY, Louise, M.

IPC: A61B

CPC classification number: G01N33/9413 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2500/04 ,  G01N2500/10

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

Abstract translation: 本发明涉及诊断和治疗血液病症的方法。 具体地，本发明鉴定131,148,199,12303,13906,15513,17822,302,5677,194,14393,28059,7366,121212,1981,261,12416,270,1410,137的差异表达， 1871,13051,1847,1849,15402,340,10217,837,1761,8990和13249涉及血液学疾病感觉的组织中的基因，相对于它们在正常或非血液学疾病疾病状态中的表达和/或应答 与血液学疾病相关的操作。 本发明描述了各种血液学疾病的诊断评价和预后的方法，以及用于鉴定表现出对这种病症倾向的受试者。 本发明还提供了鉴定能够调节血液学疾病的化合物的方法。 本发明还提供了用于鉴定和治疗化合物作为血液学疾病治疗的方法。

公开(公告)号：WO2003051180A3

公开(公告)日：2003-06-26

申请号：PCT/US2002/040194

申请日：2002-12-17

Applicant: MILLENNIUM PHARMACEUTICALS, INC. ,  CARROLL, Joseph, M. ,  HEALY, Aileen

Inventor： CARROLL, Joseph, M. ,  HEALY, Aileen

IPC: A01N61/00

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 252, 304, 1980, 14717, 9941, 19310, OR 17832 genes in tissues relating to hematological disorders disease states, and/or in response to manipulations relevant to evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

公开(公告)号：WO03041652A2

公开(公告)日：2003-05-22

申请号：PCT/US0236473

申请日：2002-11-13

Applicant: MILLENNIUM PHARM INC ,  CARROLL JOSEPH M

Inventor： CARROLL JOSEPH M

IPC: A61K38/16 ,  A61K38/48 ,  A61K39/00 ,  C12N15/55 ,  C12N15/56 ,  C12N15/57 ,  A61K

CPC classification number: A61K39/00 ,  A61K38/16 ,  A61K38/4813 ,  A61K2039/53 ,  A61K2300/00

Abstract: The invention provides isolated nucleic acids molecules, designated 18080 nucleic acid molecules, which encode serine carboxypeptidase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18080 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18080 gene has been introduced or disrupted. The invention still further provides isolated 18080 proteins, fusion proteins, antigenic peptides and anti-18080 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. Methods utilizing compositions of the invention to treat, prevent or diagnose hematopoietic disorders, e.g., erythroid-associated disorders, are also provided.

Abstract translation: 本发明提供了编码丝氨酸羧肽酶成员的分离的核酸分子，命名为18080核酸分子。 本发明还提供了反义核酸分子，含有18080个核酸分子的重组表达载体，导入了表达载体的宿主细胞和导入或破坏了18080基因的非人转基因动物。 本发明还提供了分离的18080蛋白，融合蛋白，抗原肽和抗18080抗体。 还提供了利用本发明组合物的诊断方法。 还提供了利用本发明组合物治疗，预防或诊断造血功能紊乱，例如红细胞相关疾病的方法。

公开(公告)号：WO03039476A2

公开(公告)日：2003-05-15

申请号：PCT/US0235827

申请日：2002-11-07

Applicant: MILLENNIUM PHARM INC ,  CARROLL JOSEPH M

Inventor： CARROLL JOSEPH M

IPC: C12N15/09 ,  A61K20060101 ,  A61K31/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P7/00 ,  C07H21/00 ,  C12N5/06 ,  C12Q1/02 ,  C12Q1/37 ,  C12Q1/48 ,  C12Q1/68 ,  G01N33/567 ,  G01N33/574 ,  A61K

CPC classification number: G01N33/57426 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 232, 2059, 10630, 12848, 13875, 14395, 14618, 14692 or 58874 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

Abstract translation: 本发明涉及诊断和治疗血液病症的方法。 具体地，本发明鉴定了与血液学障碍感觉相关的组织中相对于它们在正常或非血液学疾病中的表达的疾病状态中的232,2059,10630,12848,13875,14395,14618,13975,14395,14618,1492或58874基因的差异表达 ，和/或响应于与血液学疾病相关的操作。 本发明描述了各种血液学疾病的诊断评价和预后的方法，以及用于鉴定表现出对这种病症倾向的受试者。 本发明还提供了鉴定能够调节血液学疾病的化合物的方法。 本发明还提供了用于鉴定和治疗化合物作为血液学疾病治疗的方法。

公开(公告)号：WO2004072242A3

公开(公告)日：2004-08-26

申请号：PCT/US2004/003417

申请日：2004-02-05

Applicant: MILLENNIUM PHARMACEUTICALS, INC. ,  KELLY, Louise, M. ,  CARROLL, Joseph, M. ,  FARLOW, Deborah ,  HEALY, Aileen

Inventor： KELLY, Louise, M. ,  CARROLL, Joseph, M. ,  FARLOW, Deborah ,  HEALY, Aileen

IPC: G01N33/53

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 and 5014 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.